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ABSTRACT 
An efficient synthesis of 2-substituted O4-cyclohexylmethyl-5-nitroso-6-aminopyrimidines from 6-
amino-2-mercaptopyrimidin-4-ol has been developed and used to prepare a range of derivatives for 
evaluation as inhibitors of cyclin-dependent kinase 2 (CDK2). The structure activity relationships 
(SARs) are similar to those observed for the corresponding O6-cyclohexylmethoxypurine series 
with the 2-arylsulfonamide and 2-arylcarboxamide derivatives showing excellent potency. Two 
compounds, 4-(6-amino-4-cyclohexylmethoxy-5-nitrosopyrimidin-2-ylamino)-N-(2-
hydroxyethyl)benzenesulfonamide (7q) and 4-(6-amino-4-cyclohexylmethoxy-5-nitrosopyrimidin-
2-ylamino)-N-(2,3-dihydroxypropyl)benzenesulfonamide (7s), were the most potent with IC50 
values of  0.7 ± 0.1 and 0.8 ± 0.0 nM against CDK2, respectively. The SARs determined in this 
study are discussed with reference to the crystal structure of 4-(6-amino-4-cyclohexylmethoxy-5-
nitrosopyrimidin-2-ylamino)-N-(2,3-dihydroxypropyl)benzenesulfonamide (7j) bound to 
phosphorylated CDK2/cyclin A. 
INTRODUCTION 
The progression of cells through the cell-cycle is a highly ordered process, which is strictly 
controlled by the cyclin-dependent kinase (CDK) family of enzymes and their cyclin partners. 
Regulation of the serine-threonine kinase activity of specific CDKs, necessary to allow the cells to 
pass through cell-cycle checkpoints, is achieved by the binding of the cyclin partner and 
phosphorylation to produce the fully activated protein kinase complex.1 In cancer, the presence of 
oncogenic signalling pathways, or the absence of control resulting from the loss or mutation of 
tumour suppressor genes, inevitably results in abnormal cell cycle control and increased 
CDK/cyclin activity.2, 3 For this reason, the development of potent and selective CDK inhibitors has 
become an important therapeutic goal.4-6 
The development of potent and selective small-molecule ATP-competitive kinase inhibitors has 
been successful for a number of therapeutic targets. New drugs have entered clinical use, notably 
imatinib that inhibits Bcr-Abl-kinase and c-Kit kinase, gefitinib and erlotinib which target the 
EGFR tyrosine kinase, and lapatinib, a dual EGFR, Her2  tyrosine kinase inhibitor.7 A large number 
small molecule inhibitors of CDK2 have been reported based on a structurally diverse range of 
scaffolds. These include derivatives of the monoheterocycles - pyrimidine,8 [1,2,4]triazole,9 
pyrazole,10 pyridine11; biheterocycles – purine,12-15 [1,3,5]triazine-pyridine,16 1,4,5,6-
tetrahydropyrrolo[3,4-c]pyrazole,17 pyrazolo[3,4-c]pyridazine,18 triazolo[1,5-a]pyrimidine,19 
pyrazolo[1,5a]pyrimidine;20 triheterocycles - benzodipyrazole,21 aminoimidazo[1,2a]pyridine.22 All 
the inhibitors are competitive with ATP, and vary in their potency and selectivity among the other 
members of the CDK family and also other unrelated kinases. 
The biological effects of inhibition of CDK2 have been studied using molecular genetic approaches 
in cell lines and knockout animals. Experiments in cell-lines have produced conflicting results, 
suggesting that CDK2 is not essential for proliferation in all situations.23, 24 Additionally, CDK2-
knockout mice have been generated which are viable and apparently normal, other than being 
infertile.25, 26 These results cast doubt over the inhibition of CDK2 as a valuable therapeutic target. 
However, it should be noted that the absence or attenuation of a protein through genetic knockdown 
or knockout does not exactly mirror the situation where a protein is present at its usual cellular 
concentration, but is inactivated through a small-molecule inhibitor.  Furthermore, a number of 
studies to date have demonstrated anti-tumour activity in tumour models with CDK2 inhibitors that 
have significant activity against other CDKs, including CDK4, CDK7 and CDK9,27-29 and the first 
generation of CDK inhibitors has entered clinical trials as anti-tumour agents.30 
We have previously reported the purine NU6102 (1) as a highly potent and selective ATP-
competitive inhibitor of CDK2 (Ki = 6 nM), developed from the lead compound O6-
cyclohexylmethoxyguanine NU2058 (CDK2 Ki = 12 μM).31, 32 The X-ray crystal structure of 1 
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bound to CDK2 shows the purine core making a triplet of hydrogen bonds within the ATP binding 
site and two hydrogen bonds between the sulfonamide group and Asp86 of CDK2. We have also 
demonstrated previously that a series of nitrosopyrimidines are CDK2 inhibitors, e.g. NU6027 (2; 
CDK2 Ki = 1.3 μM). The nitroso group induces a ‘purine-mimetic’ conformation by hydrogen 
bonding to the adjacent NH2 group. The X-ray structure of 2 in complex with CDK2 shows the 
pyrimidine binding in a similar orientation to NU2058 and 1.12 A limited series of analogues of 2 
that explored similar structural modifications to those leading to the development of 1 has been 
communicated.33 In this paper we report the synthesis of an expanded range of 2-arylamino-4-
cyclohexylmethyl-5-nitroso-6-aminopyrimidines, based on 2. The structure-activity relationships 
for the inhibition of CDK2 are discussed with reference to an X-ray crystal structure of a key 
inhibitor bound to the CDK2/cyclinA protein complex.  
 
<structures 1 and 2 here> 
RESULTS AND DISCUSSION 
Chemical Synthesis 
The initial route to the target 2,4-disubstituted pyrimidines used 2,4,6-trichloropyrimidine as the 
starting material. Substitution with bis-p-methoxybenzylamine in refluxing ethanol, gave both the 
2- and 4-substituted pyrimidines (3a and 3b), which were separable by chromatography (Scheme 
1). Unambiguous structure determination for 3a and 3b was not possible from their 1H and 13C 
NMR spectra, so an X-ray crystal structure was obtained for 3a that confirmed it as the desired 
isomer (Figure 1).  A second substitution of the 2-substituted pyrimidine 3a with p-methoxyaniline 
was achieved under more forcing conditions, in refluxing n-butanol with triethylamine as base, 
giving the 2,4-disubstituted pyrimidine 4a, accompanied by the 2,6-disubstituted product 4b, in a 
2:3 ratio. Again, X-ray crystallography was used to unambiguously assign the structure of 4a 
(Figure 1). The final substitution was carried out using sodium cyclohexylmethoxide in 
cyclohexylmethanol, giving the trisubstituted pyrimidine 5. Removal of the p-methoxybenzyl 
protecting groups with TFA, followed by nitrosation, gave 6-amino-2-anilino-4-
cyclohexylmethoxy-5-nitrosopyrimidine (7a). An attempt to follow the same reaction scheme using 
4-amino-N,N-dimethylbenzenesulfonamide, however, met with failure. The lack of regioselectivity 
in the initial substitution, and the formation of unwanted substitution products in the second step of 
Scheme 1, rendered this route unsuitable for the synthesis of a series of analogues.  
<Scheme 1 here> 
<Figure 1 here> 
We considered that a more efficient synthesis could be achieved from 6-amino-2-
mercaptopyrimidin-4-ol, which would allow the introduction of the anilino and cyclohexylmethoxy 
substituents and avoid the complications of regioselectivity seen in Scheme 1. The 
mercaptopyrimidine was alkylated to give the n-butyl sulfide (8) in excellent yield (Scheme 2), and 
then the cyclohexylmethoxy group was introduced under Mitsonubu conditions to give 9 in good 
yield. Direct displacement of the butylsulfide group from 9 with anilines proved unsuccessful, so 
the leaving group ability was improved by oxidation to the sulfone (10) using mCPBA, prior to 
displacement with the appropriate anilines to give the 2-arylaminopyrimidines 6b-s. The optimum 
conditions for the sulfone displacement were found to be with trifluoroethanol as solvent and five 
equivalents of TFA as catalyst, as described previously.34 Under these conditions, the displacements 
with various anilines proceeded in moderate to good yields. For the final step, nitrosation under 
standard conditions gave the desired 5-nitrosopyrimidines (7b-s).12 
<Scheme 2 here> 
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<Table 1 here> 
SAR Discussion 
A series of 2-arylamino-5-nitrosopyrimidines was prepared and evaluated for CDK2 inhibitory 
activity and the results are shown in Table 1. Compounds lacking the 5-nitroso group (6b, 6e, 6g, 
6h, and 6j) are at least 103 times less potent as CDK2 inhibitors compared with their 5-nitroso 
counterparts (7b, 7e, 7g, 7h, and 7j). These results are consistent with previous findings which 
showed that the 5-nitroso group forms an intramolecular hydrogen bond with the 6-amino group 
and orientates one of the amino NH bonds correctly to interact with the backbone carbonyl of Glu 
81 of CDK2.12, 35 
As predicted from the results in the comparable purine series,32 the nature and position of the 
substituent on the N2-aryl moiety has a profound effect on the CDK inhibitory activity. Small-
lipophilic substituents at the 3-position (7b, 7d, 7e) produced modest improvements in activity 
compared with the parent compound (2, IC50 =  2.2 ± 0.6 μM for CDK2), whereas polar substituents 
attached by a methylene group (7g and 7i) resulted in up to 60-fold improvements in potency. In 
line with the purine series, the introduction of polar substituents at the 4-aryl position proved 
favourable. Compounds bearing 4-hydroxy or 4-carboxamido substituents (7c and 7j) showed 100-
fold  improvement in activity, whereas the 4-sulfonamido substituent 7m gave a 2000-fold 
improvement in activity over the parent 2.  
We have previously reported the X-ray crystal structure of carboxamide 7j bound to the 
CDK2/cyclin A phosphorylated on Thr160 (T160pCDK2/cyclin A)  (Figure 2, PDB accession code 
1OGU).8 Compounds 7j and 2 bind in a similar orientation within the CDK2 ATP-binding site. 
Compound 7j forms three hydrogen bonds with the hinge region of the enzyme, namely N6 to the 
peptide carbonyl of Glu81, and N1 and N2 to the backbone amide and carbonyl groups of  Leu83, 
respectively. The 5-nitroso group forms the anticipated intramolecular hydrogen bond to N6, 
locking the molecule into a purine-like conformation. The N2 aryl ring stacks against the peptide 
backbone between His84 and Gln85. The orientation of the carboxamide substituent could not be 
determined unambiguously. However, the formation of an additional hydrogen bond from a 
carboxamide NH to the side chain of Asp86 is a reasonable interpretation of the data and is 
consistent both with the SARs and the observed structure of the sulfonamide 2. The interaction of at 
least one carboxamide or sulfonamide NH with CDK2 can be inferred from the loss of activity 
observed for the dialkylcarboxamides (7k and 7l) and the diethylsulfonamide (7n), consistent with 
the structural data for 7j.  
<Figure 2 here> 
The X-ray crystal structure of the T160pCDK2/cyclin A/purine 2 complex, shows that only one of 
the sulfonamide protons makes a hydrogen bond to Asp68, suggesting that substitution of the other 
position may be favourable.32 It was anticipated that the pyrimidines would behave similarly. The 
monoalkylsulfonamides (7o-s) retained potent activity, in particular against CDK2. The 2-
hydroxyethyl- and 2,3-dihydroxypropylsulfonamides (7q and 7s) displayed a modest improvement 
in activity compared with the parent 7m, and are amongst the most potent CDK2 inhibitors reported 
to date. The improvement in activity suggests that additional interactions may be formed between 
the additional hydroxyl group(s) and the enzyme. The formation of additional favourable hydrogen 
bonding interactions, in the region accessed by the sulfonamide substituents, has been observed in 
the purine series. For example, the X-ray structure of sulfoxide 8 bound to CDK2 shows the amine 
and hydroxyl groups bound to the side-chain carboxyl group of Asp86.36 
<Structure 8 here> 
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The CDK selectivity of two of the most potent CDK2 inhibitors, the sulfonamide 7m and the 
hydroxyethylsulfonamide 7q, was evaluated using a panel of CDK1/cyclinB, CDK4/cyclinD, 
CDK7/cyclinH, and CDK9/cyclinT (Table 2). Both inhibitors showed excellent selectivity for 
CDK2, with around 100-fold selectivity observed against CDK1/cyclinB, and around 1000-fold 
selectivity against the other CDK/cyclin complexes. 
<Table 2 here> 
CONCLUSIONS 
Synthesis of 2-substituted O4-cyclohexylmethyl-5-nitroso-6-aminopyrimidines from 2,4,6-
trichloropyrimidine required the separation of mixtures of regioisomers at the first two steps and 
was not amenable to the introduction of a range of substituents. The improved route, from 6-amino-
2-mercaptopyrimidin-4-ol,33 has allowed the preparation of a range of derivatives for evaluation as 
inhibitors of CDK2. The structure activity relationships observed follow similar trends to those for 
the corresponding O6-cyclohexylmethoxypurine series, with the 2-arylsulfonamide and 2-
arylcarboxamide derivatives showing excellent potency. Two compounds, 4-(6-amino-4-
cyclohexylmethoxy-5-nitrosopyrimidin-2-ylamino)-N-(2-hydroxyethyl)benzenesulfonamide (7q) 
and 4-(6-amino-4-cyclohexylmethoxy-5-nitrosopyrimidin-2-ylamino)-N-(2,3-
dihydroxypropyl)benzenesulfonamide (7s), showed excellent potency against CDK2, with an IC50 
value of  0.7 ± 0.1 and 0.8 ± 0.0 nM. Excellent selectivity within the CDK family was found for 7m 
and  7q. These compounds are among the most potent and selective CDK2 inhibitors reported to 
date. 
EXPERIMENTAL 
Reagents were purchased from fine chemicals vendors, and used as received unless otherwise 
stated. Solvents were purified and stored according to standard procedures. Petrol refers to that 
fraction in the boiling range 40-60 °C. Melting points were obtained on a Stuart Scientific SMP3 
apparatus and are uncorrected. Thin layer chromatography was performed using silica gel plates 
(Kieselgel 60F254; 0.2 mm), and visualized with UV light or potassium permanganate. 
Chromatography was conducted under medium pressure on silica (BDH silica gel 40-63 µm). 
Proton (1H) and carbon (13C) nuclear magnetic resonance (NMR) spectra were recorded on a Bruker 
Avance 300 spectrometer at 300 MHz or 75 MHz, repectively, employing TMS or the solvent as 
internal standard. NH signals appeared as broad singlets (br s) exchangeable with D2O. Mass 
spectra were determined on a Micromass Autospec M spectrometer in electron impact (EI) mode. 
Liquid Chromatography-Mass Spectrometry (LCMS) was carried out on a Micromass Platform 
instrument operating in positive and negative ion electrospray mode, employing a 50 x 4.6 mm C18 
column (Supelco Discovery or Waters Symmetry) and a 15 minute gradient elution of 0.05% formic 
acid and methanol (10-90%). IR spectra were recorded on a Bio-Rad FTS 3000MX diamond ATR. 
Elemental analyses were performed by Butterworth Laboratories, Middlesex, UK. High-resolution 
mass spectra were recorded at the EPSRC Mass Spectrometry Service, Swansea, UK. 
2,6-Dichloro-N,N-bis(4-methoxybenzyl)pyrimidin-4-amine (3a) 
A mixture of 2,4,6-trichloropyrimidine (2.2 mL, 19 mmol) and bis-(4-methoxybenzyl)amine (4.8 g, 
19 mmol) and triethylamine (3.2 mL, 22.7 mmol) in n-butanol (20 mL) was heated to 75 oC for 3 h, 
then allowed to cool and concentrated in vacuo. Chromatography (silica; 10% ethyl acetate, petrol) 
gave 3a as a white solid (2.5 g, 33%) mp 129-131 oC; νmax/ cm-1 3000, 2838 1610, 1568, 1487, 
1127.  δH (300 MHz, d6-DMSO) 3.77 (3H, s, OCH3), 4.64 (2H, br s, NCH2), 4.82 (2H, br s, NCH2), 
6.89 (1H, s, H5), 6.94 (4H, d, J = 8.5 Hz, ArH),  6.94 (4H, d, ArH), 7.17 (2H, br s, ArH), 7.26 (2H, 
br s, ArH); δC (125 MHz, d6-DMSO; DEPT) 50.58 (sp2), 55.82 (sp3), 101.59 (sp), 114.78 (sp), 
128.87 (sp), 129.94 (sp), 159.18 (q), 159.42 (q), 159.74 (q), 164.28 (q). m/z (ESI+) = 404 [M+H]+. 
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HRMS (EI) m/z Calcd. for C20H19Cl2N3O2: 404.0927 [M+H]+. Found 404.0932 [M+H]+. 
C20H19Cl2N3O2: requires C, 59.42; H, 4.74; N, 10.39; found C, 59.41; H, 4.73 N, 10.33% 
6-Chloro-N4,N4-bis(4-methoxybenzyl)-N2-(4-methoxyphenyl)pyrimidine-2,4-diamine (4) 
A mixture of 3a (1.2 g, 2.9 mmol), p-anisidine (0.44 g, 3.6 mmol), anhydrous triethylamine (0.50 
mL, 3.6 mmol), n-butanol (8 mL) and anhydrous DMSO (2 mL) was heated to 95 oC for 3 days, 
then allowed to cool and concentrated in vacuo. Water (50 mL) was added and the mixture was 
extracted with ethyl acetate (3 x 50 mL). The combined organic extracts were dried (NaSO4) and 
concentrated in vacuo. Chromatography (silica; 30% ethyl acetate, petrol) gave 4 as a red solid 
(0.43 g, 30%) mp 142-145 °C. υmax/ cm-1: 3263, 3110, 2954-2930, 2831, 1605, 1553, 1500, 1224. 
λmax (EtOH): 274, 227 nm. δH (300 MHz, CDCl3): 3.66 (6H, s, 2 x OCH3), 3.69 (3H, s, OCH3), 4.52 
(4H, br, 2 x N-CH2-), 5.89 (1H, s, CH), 6.66 (2H, d, J = 8.9 Hz), 6. 76 (4H, d, J = 8.6 Hz), 7.01 (4H, 
d, J = 8.6 Hz), 7.28 (2H, d, J = 8.9 Hz) ppm. δC (75 MHz, CDCl3): 50.9 (N-CH2), 55.6 (OCH3), 
55.8(OCH3), 93.2, 114.5, 114.7, 122.4, 128.8, 129.3, 133.1, 156.0, 159.6, 159.8, 160.5, 164.4 ppm. 
m/z (ESI+) 491.24 [M+H]+. HRMS (EI) m/z Calcd. for C27H17ClN4O3: 491.1844 [M+H]+. Found 
491.1841 [M+H]+. C27H27ClN4O3 requires; C, 66.05; H, 5.54; N, 11.41; found C, 65.83; H, 5.57; N, 
11.34%  
also N4,N4-bis(4-methoxybenzyl)-N2,N6-bis(4-methoxyphenyl)pyrimidine-2,4,6-triamine 
(0.64 g, 45%) mp 130-133 0C. υmax/ cm-1: 3330 (NH), 3132, 2992(CH arom), 2897 (CH2), 2835 
(OCH), 1579, 1537 (C=C, C=N), 1502 (NR3), 1230 (CH30). λmax (EtOH): 275, 227 nm. δH (300 
MHz, CDCl3): 3.60 (3H, s, OCH3), 3.63(3H, s, OCH3), 3.65 (6H, s, 2 x OCH3), 4.46 (4H, br, 2 x N-
CH2-), 5.13 (1H, s, CH), 6.60-6.66 (4H, dd, J = 9.1. Hz), 6. 71 (4H, d, J = 8.6 Hz), 6,85 (2H, d, J = 
8.9), 6.98 (4H, d, J = 8.6 Hz), 7.28 (2H, d, J = 9.0 Hz) ppm. δC (75 MHz, CDCl3): 50.7 (N-CH2), 
55.7, 55.8, 55.9 (OCH3), 75.9, 114.4, 114.5, 114.9, 121.8, 124.9, 128.9, 130.7, 132.9, 134.3, 155.3, 
156.9, 159.3, 159.9, 162.8, 164.3 ppm. m/z (ESI+)  578.34 [M+H]+. 
6-(Cyclohexylmethoxy)-N4,N4-bis(4-methoxybenzyl)-N2-(4-methoxyphenyl)pyrimidine-2,4-
diamine (5) 
Sodium (0.036 g, 1.55 mmol) was heated in cyclohexylmethanol (1.5 mL) at 120 oC under N2 for 1 
h. 4 (0.38 g, 0.77 mmol) was added and the mixture heated at 160 oC for 3h, then allowed to cool, 
diluted with petrol (60 mL), and washed with water (3 x 30 mL). The organic layer was dried 
(Na2SO4) and concentrated in vacuo. Chromatography (silica; 10% ethyl acetate, petrol) gave 5 as a 
pale yellow oil containing residual cyclohexylmethanol, which was used without further 
purification. (0.88 g). δH (300 MHz, d6-DMSO) 0.84-1.38 (m, C6H11), 1.68-1.77 (m, C6H11), 3.71 
(3H, s, OCH3), 3.76 (6H, s, 2 x OCH3), 4.03 (2H, d, J = 6.7 Hz, OCH2), 4.66 (4H, br s, 2 x NCH2), 
5.34 (1H, s, H5), 6.77 (2H, d, J = 9.0 Hz, ArH), 6.92 (4H, d, J = 8.5 Hz, ArH), 7.19 (4H, d, J = 8.0 
Hz, ArH), 7.58 (2H, d, J = 9.0 Hz, ArH), 8.86 (1H, s, D2O ex, NH). m/z (ESI+) = 569 [M+H]+. 
6-(Cyclohexylmethoxy)-N2-(4-methoxyphenyl)pyrimidine-2,4-diamine (6a) 
A solution of 5 (0.44 g, corrected to 0.2 mmol) in trifluoroacetic acid (5 mL) was heated to 60 oC 
for 5 h, then allowed to cool, concentrated in vacuo, then diluted with water (20 mL) and extracted 
with ethyl acetate (3 x 20 mL). The combined organic layers were dried (Na2SO4) and concentrated 
in vacuo. Chromatography (silica; 30% ethyl acetate, petrol) gave 6a as a pale brown solid (0.06 g, 
91%) m.p. 102-105 oC. UV λmax (EtOH): 276, 205 nm. υmax/ cm-1: 3341, 3221, 3070, 2966, 2823, 
1520, 1496, 1219. δH (300 MHz, CDCl3): 0.96-1.19 (5H, m, C6H11), 1.57-1.68 (6H, m, C6H11), 3.66 
(3H, s, OCH3), 3.93 (2 H, d, J = 6.3 Hz), 4.84 (2H, br, NH2), 5.19 (1H, s, CH), 6.72 (2H, d, J = 9.3 
Hz), 7.38 (2H, d, J = 9.3 Hz) ppm. δC (75 MHz, CDCl3): 26.1, 26.8, 30.1, 37.8, 55.8, 71.6, 79.2, 
114.3, 121.7, 133.7, 155.6, 159.9, 165.3, 171.7 ppm. m/z (ESI+) 329.28 [M+H]+. HRMS (EI) m/z 
calcd. for C18H24N4O2: 329.1972 [M+H]+; found 329.1973 [M+H]+. 
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6-(Cyclohexylmethoxy)-N2-(4-methoxyphenyl)-5-nitrosopyrimidine-2,4-diamine (7a) 
To a solution of  6a (0.05 g, 0.15 mmol) in 30% acetic acid and water (5 mL) at 80 oC was added 
sodium nitrite (0.014 g, 0.2 mmol) in water (0.2 mL) giving a brown precipitate. Heating was 
continued 2 h then the mixture was allowed to cool to rt, and concentrated in vacuo. The residues 
were disolved in ethyl acetate (40 mL) and washed with Na2CO3 solution (3 x 20 mL) and water (2 
x 20 mL). The combined organic layers were dried (Na2SO4) and concentrated in vacuo. 
Chromatography (silica; 5% methanol, ethyl acetate) followed by HPLC (C18, acetonitrile, water) 
gave 7a as a dark green solid (0.044 g, 26%) m.p. 168-171 oC. υmax/ cm-1: 3288, 3070, 2923, 2851, 
1557, 1496, 1446, 1240. λmax (EtOH): 368, 292, 244 nm. δH (300 MHz, d6-acetone) 0.74-1.79 (11H, 
m, C6H11), 3.67 (3H, s, OCH3), 4.24 (2H, s, OCH2), 6.76 (2H, br s, ArH), 7.32 (1H, br s, D2O ex, 
NH), 7.66(2H, br s, ArH),  9.07 (1H, s, D2O ex, NH), 10.33 (1H, s, D2O ex, NH). m/z (ESI+) = 358 
[M+H]+. δC (75 MHz, DMSO): 25.4, 26.3, 29.5, 37.2, 55.7, 72.3, 114.2, 123.5, 131.9, 140.4, 150.3, 
156.5, 160.2, 171.6 ppm. m/z (ESI+) 358.26 [M+H]+. HRMS (ESI+) m/z calcd. for C18H23N5O3: 
358.1874 [M+H]+; found 358.1878 [M+H]+. C18H23N5O3. requires C, 60.49; H, 6.49; N, 19.59; 
found C, 60.87; H, 6.49, N, 18.95% 
 
 
6-Amino-2-n-butylsulfanyl-H3-pyrimidin-4-one (8) 
6-Amino-2-mercaptopyrimidin-4-ol monohydrate (5.0 g, 31 mmol) was slurried in EtOH (30 mL) at 
50 oC, and treated with NaOH (3.25 M, 10 mL, 32.1 mmol) and the mixture stirred 30 min. 1-
Bromobutane (3.45 mL, 32.1 mmol) was added dropwise to the slurry and stirring continued 18 h.  
Water (10 mL) was added and the mixture stirred 30 min. After cooling to room temperature, the 
mixture was concentrated in vacuo giving 8 as an off-white solid (5.70g, 92%):  m.p. 183-186 oC. 
Lit. 175 oC 37; νmax/ cm-1 1570, (C=N), 1601 (C=C), 2858-2928 (CH3, CH2), 3271, 3464 (OH, NH2). 
δH (300 MHz, d6-DMSO) 0.89 (3H, t, J = 7 Hz, CH3), 1.31-1.43 (2H, m, CH3CH2), 1.53-1.63 (2H, 
m, CH3CH2CH2), 3.06 (2H, t, J = 7 Hz, SCH2), 4.87 (1H, s, H5), 6.43 (2H, br s, NH2, exchangeable 
with D2O); δC (125 MHz, d6-DMSO) 13.5 (CH3), 21.3 (CH3CH2), 29.0 (CH3CH2CH2CH2S), 31.0 
(CH3CH2CH2CH2S), 81.1 (C5), 163.5 (C6). m/z (ESI+) = 200 [M+H]+. 
2-n-Butylsulfanyl-4-cyclohexylmethoxypyrimidin-6-ylamine (9) 
To a mixture of 8 (1.50 g, 7.53 mmol), cyclohexylmethanol (1.39 mL, 11.30 mmol), and PPh3 (2.96 
g, 11.30 mmol) in THF (50 mL) was added DEAD (1.78 mL, 11.30) dropwise over 20 min at 0 oC, 
and stirring continued 24 h. The mixture was concentrated in vacuo yielding a yellow oil which was 
stirred in diethyl ether at 0 oC, forming a white precipitate, which was removed by filtration.  The 
filtrate was collected and concentrated in vacuo.  Chromatography (silica;20% ethyl acetate, petrol) 
followed by recrystallisation (MeOH) gave 9 as a white solid (1.60 g, 72%):  m.p. 79-82 oC; νmax/ 
cm-1 1547, 1583 (C=N), 1631 (C=C), 2850-3156 (CH3, CH2), 3294-3425 (NH2). δH (200 MHz, d6-
DMSO) 1.08 (3H, t, J = 7 Hz, CH3), 1.22-1.62 (9H, m, C6H11+ CH3CH2CH2), (6H, m, C6H11), 3.12 
(2H, t, J = 7 Hz, SCH2), 4.18 (2H, d, J = 6 Hz, OCH2), 5.57 (1H, s, H5), 6.80 (2H, br s, NH2, 
exchangeable with D2O) ppm; δC (50 MHz, d6-DMSO) 13.5 (CH3), 21.5 (CH3CH2), 25.5 (C6H11), 
26.3 (C6H11), 29.3 (C6H11), 31.6 (C6H11), 32.1 (CH3CH2CH2CH2S), 36.89 (CH3CH2CH2CH2S), 
66.6, 70.3 (OCH2), 81.57 (C5), 165.14 (C2), 168.79 (C6), 169.17 (C4) ppm. m/z (ESI+) = 296 
[M+H]+. C15H25N3OS requires: C, 60.98; H, 8.53; N, 14.22; S, 10.85%; found: C, 61.01; H, 8.52; 
N, 13.85; S, 10.42. 
2-(n-Butane-1-sulfonyl)-4-cyclohexylmethoxypyrimidin-6-ylamine (10)  
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To a stirred solution of 9 (1.0 g, 3.38 mmol) in DCM (20 mL) was added m-CPBA (2.34 g, 13.5 
mmol) and stirring continued for 17 h.  The mixture was concentrated in vacuo giving a yellow 
solid which was extracted into ethyl acetate (2 x 20 mL). The combined extracts were washed with 
saturated sodium sulfite solution (30 mL) and aqueous NaHCO3 solution (30 mL), then dried 
(Na2SO4) and concentrated in vacuo yielding 10 as an off-white solid (0.99 g, 89%). 
Recrystallisation (ethyl acetate, petrol) gave a white solid: m.p. 141-143 oC; νmax/ cm-1 1130 (SO2 
sym str.), 1300 (SO2 asym. str.) 1595 (C=N), 1635 (C=C), 2852-3212 (CH3, CH2), 3323, 3424 
(NH2). δH (300 MHz, CDCl3) 0.89 (3H, t, J = 7 Hz, CH3), 1.15-1.18 (5H, m, C6H11), 1.41 (2H, q, J 
= 7, 15 Hz, CH3CH2CH2), 1.66-1.79 (8H, m, C6H11+ CH3CH2CH2), 3.32-3.38 (2H, m, SO2CH2), 
4.05 (2H, d, J = 6 Hz, OCH2), 5.48 (2H, br s, NH2, exchangeable with D2O), 5.75 (1H, s, H5) ppm; 
δC (75 MHz, CDCl3) 14.0 (CH3), 22.2 (CH3CH2), 24.5 (CH3CH2CH2), 26.7 (C6H11), 27.0 (C6H11), 
30.1 (C6H11), 37.7 (C6H11), 51.1 (CH2SO2), 73.0 (OCH2), 89.1 (C5), 164.7 (C2), 165.5 (C6), 171.2 
(C4). m/z (ESI+) = 328 [M+H]+. C15H25N3O3S requires: C, 55.02; H, 7.70; N, 12.83; found C, 54.88; 
H, 7.71; N, 12.63%. 
General Procedure A. 
To solution of 10 (0.20 g, 0.61 mmol) and the appropriate aniline (2 mol. eq.) in TFE (4 mL) was 
added TFA (0.24 mL, 3.05 mmol). The mixture was stirred for 10 min at rt, then heated under 
reflux for a further 2 h, and concentrated in vacuo yielding a white solid.  The solid was extracted 
into ethyl acetate (2 x 20 mL). The combined extracts were washed with copious amounts of water 
(100 mL), then dried (Na2SO4), and concentrated in vacuo.  
4-(6-Amino-4-cyclohexylmethoxypyrimidin-2-ylamino)benzenesulfonamide (6m) 
General Procedure A: C (0.30 g, 0.92 mmol), 4-aminobenzenesulfonamide (0.32 g, 1.84 mmol), 
TFE (3 mL), TFA (0.38 mL, 4.60 mmol). HPLC (C18; methanol, water)gave 6m as a white solid 
(0.24 g, 69%): m.p. 177-179 oC; νmax/ cm-1 1564 (C=C, C=N str.), 1620 (SO2NH2, NH2 def.), 2853-
2925 (CH2), 3104-3216 (=C-H str.), 3346 (asym + sym N-H str.), 3471 (NH2); λmax = 210 and 296 
nm. δH (300 MHz d6-DMSO) 0.98-1.26 (5H, m, C6H11), 1.68-1.78 (6H, m, C6H11), 4.01 (2H, d, J = 
6 Hz, CH2O), 5.29 (1H, s, H5), 6.43 (2H, s, NH2 exchangeable with D2O), 7.13 (2H, s, NH2 
exchangeable with D2O), 7.63 (2H, d, J = 9 Hz, ArH), 7.93 (2H, d, J = 9 Hz, ArH), 9.34 (NH, 
exchangeable with D2O) ppm. m/z (ESI+) = 378 [M+H]+. C17H23N5O3S·0.33CH3OH requires: C, 
53.54; H, 6.32; N, 18.04; found: C, 53.50; H, 6.20; N, 18.04%. 
4-(6-Amino-4-cyclohexylmethoxypyrimidin-2-ylamino)-N-(2-
hydroxyethyl)benzenesulfonamide (6q) 
General Procedure A: 9 (0.11 g, 0.33 mmol), amino-N-(2-hydroxyethyl)benzenesulfonamide (0.14 
g, 0.65 mmol) TFE (3 mL), TFA (0.13 mL, 1.63 mmol). HPLC (C18; methanol, water) gave 6q as a 
white solid (0.09 g, 0.22 mmol, 66%). m/z (ESI+) = 422 [M+H]+.  
General Procedure B: Nitrosation. 
The appropriate pyrimidine was dissolved in aqueous acetic acid (30%; 3 mL) and the solution was 
heated to 80 oC, then sodium nitrite (0.02 g, 0.35 mmol) in water (0.2 mL) was added dropwise. 
The mixture was stirred for a further 2 h, then extracted into ethyl acetate (30 mL). The extract was 
washed with water (30 mL), dried (Na2SO4) and concentrated in vacuo.  
4-(6-Amino-4-cyclohexylmethoxy-5-nitrosopyrimidin-2-ylamino)benzenesulfonamide (7m)  
General Procedure B: 6m (0.08 g, 0.20 mmol). HPLC (C18; methanol, water) gave 7m as a green 
solid (0.02 g, 25%): m.p. 159-162 oC; νmax/ cm-1 1528 (N=O str.), 1633 (NH2 def.), 2846-3040 (-
CH2-), 3280 (asym + sym N-H str.), 3364 (NH2); λmax = 362 nm. δH (300 MHz d6-DMSO) 1.00-
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1.23 (5H, m, C6H11), 1.71-1.88 (6H, m, C6H11), 4.43 (2H, d, J = 6 Hz, CH2O), 7.29 (2H, s, NH2 
exchangeable with D2O), 7.73 (2H, d, J = 8 Hz, ArH), 8.00 (2H, s br, ArH), 8.60 (NH, 
exchangeable with D2O), 10.25 (1H, s, NH, exchangeable with D2O), 10.60 (NH, exchangeable 
with D2O) ppm. m/z (ESI+) = 407 [M+H]+. C17H22N6O4S·0.5CH3CO2H requires: C, 49.53; H, 5.54; 
N, 19.25; found: C, 49.44; H, 5.37; N, 19.53%. 
4-(6-Amino-4-cyclohexylmethoxy-5-nitrosopyrimidin-2-ylamino)-N-(2-
hydroxyethyl)benzenesulfonamide (7q)  
General Procedure B: 6q (0.09 g, 0.22 mmol). Recrystallisation (MeOH) gave 7q as a green solid: 
m.p. 193-195 °C; νmax/ cm-1 1522 (N=O str.), 1576 (C=N, C=C), 2852-2926 (-CH2-), 3100-3267 
(NH2, OH); λmax = 362, 263, 239 and 208 nm. δH (300 MHz d6-DMSO) 1.05-1.30 (5H, m, C6H11), 
1.50-1.88 (6H, m, C6H11), 2.78 (2H, q, J = 6 Hz, NHCH2), 3.36 (2H, t, CH2OH), 4.39 (2H, d, J = 6 
Hz, CH2O), 4.68 (1H, t, OH exchangeable with D2O), 7.40 (1H, t, NHCH2 exchangeable with D2O), 
7.71 (2H, d, J = 8 Hz, ArH), 7.97 (2H, d,  J = 8 Hz, ArH) 8.50 (1H, s, NH exchangeable with D2O) 
ppm. m/z (ESI+) = 451 [M+H]+. C19H26N6O5S·0.5CH3CO2H requires: C, 49.99; H, 5.87; N, 17.49; 
found: C, 49.67; H, 5.26; N, 17.60%. 
Biological Evaluation 
Compounds were assayed for the inhibition of human cyclin-dependent kinases 1 and 2, as 
described previously.12 The final ATP concentration within the assay was 12.5 μM. 
X-Ray Crystallography§ 
Crystals of 3a and 4a were small and weakly diffracting, and data were collected at 120 K with 
synchrotron radiation (λ = 0.8462 Å) at station 16.2SMX of the Synchrotron Radiation Source at 
Daresbury Laboratory, through the EPSRC National Crystallography Service.  Crystal data for 3a: 
C20H19Cl2N3O2, Mr = 404.3, monoclinic, space group P21/c, a = 21.9143(10), b = 10.1032(5), c = 
8.7088(4) Å, β = 98.099(1)°, V = 1908.94(16) Å3, Z = 4, μ = 0.36 mm−1, 13035 data measured, 
3886 unique (Rint = 0.029), 246 refined parameters, R (F, F2 > 2σ) = 0.038, Rw (F2, all data) = 
0.098, S = 1.03, final difference map within ±0.29 e Å−3.  Crystal data for 4a: C27H27ClN4O3, Mr = 
491.0, monoclinic, space group C2/c, a = 16.9620(14), b = 10.7877(9), c = 27.228(2) Å, β = 
98.375(1)°, V = 4929.0(7) Å3, Z = 8, μ = 0.19 mm−1, 15124 data measured, 5026 unique (Rint = 
0.042), 323 refined parameters, R (F, F2 > 2σ) = 0.045, Rw (F2, all data) = 0.117, S = 1.06, final 
difference map within ±0.31 e Å−3. 
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TABLE  
Table 1: Inhibition of CDK2 by 4-cyclohexylmethoxypyrimidines. 
N
N
O
NH2N
X
R
H  
Compound R X CDK2 IC50 values (nM) or  % Inhibition at stated concentration 
2a - NO 2.2 ± 0.6 
7ab 4-OMe NO 215 ± 50 
6b 3-Br H 26000 ± 6000 
7bb 3-Br NO 500 ± 200 
7c 4-OH NO 16 ± 3 
7d 3-OMe NO 340 ± 70 
6e 3-SMe H 60000 ± 5000 
7e 3-SMe NO 400 ± 100 
7f b 4-SMe NO 120 ± 30 
6g 3-CH2CN H 
41 ± 4% 
(10 μM) 
7g 3-CH2CN NO 33 ± 3 
6h 4-CH2CN H 24000 ± 6000 
7h 4-CH2CN NO 64 ± 3 
7i 3- CH2OH NO 45 ± 21 
6jb 4-CONH2 H 59000 ± 31000 
7jb 4-CONH2 NO 34 ± 8 
6k 4-CON(CH3)2 H 
49% 
(100 μM) 
7k 4-CON(CH3)2 NO 80 ±10 
6l 4-CON(C2H5)2 H 
29 ± 9% 
(10 μM) 
7l 4-CON(C2H5)2 NO 200 ± 100 
6mb 4-SO2NH2 H 2930 ± 400 
7mb 4-SO2NH2 NO 1.0 ± 0.3 
6n 4-SO2N(C2H5)2 H 
33 ± 9% 
(10 μM) 
14 
   
7n 4-SO2N(C2H5)2 NO 86 ± 8 
7o 
4- 
H
N
S
O2
*
O
 
NO 8.1 ± 0.25 
7p 
4- N
S
H
N
S
O2
*
 
NO 19 ± 1 
7q 4- 
OH
H
N
S
O2
*
 NO 0.7 ± 0.1 
7r 
4- 
H
N
S
O2
*
OH
 
NO 1.3 ± 0.2 
7s 
4- 
H
N
S
O2
*
OH
OH
 
NO 0.8 ± 0.0 
aRef 12; bRef 8 
Table 2: Selectivity of inhibition of CDKs by 7m and 7q. 
IC50 values (nM) 
Compound 
CDK1/B CDK2/A CDK4/D CDK7/H CDK9/T 
7m 100 ± 10 1 ± 0.3 1500 ± 500 2800 ± 1300 740 ± 100 
7q 56 ± 20 0.7 ± 0.1 1300 ± 500 4800 ± 2600 2630 ± 200
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FIGURES 
Figure 1: Molecular structures of A: 3a; B: 4a from X-ray crystallography.  
A: B:  
 
 
Figure 2: A: Crystal structure of 7j bound to Thr160pCDK2/cyclin A, overall fold. CDK2 and 
cyclin A are rendered in green and gold ribbons, respectively. Compound 7j occupies the ATP 
binding site and is drawn in ball and stick mode with carbon, nitrogen, and oxygen atoms coloured 
green, red, and blue, respectively. B: Compound 7j bound to the CDK2 active site. The side chains 
of selected residues that line the CDK2 active site are included.  Hydrogen-bonds between 7j and 
CDK2 are drawn as dashed lines.  
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